{
    "title": "Roche buys U.S. rights to Roivant bowel disease drug in $7.1 billion deal",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12660851/Roche-buys-Telavant-Holdings-7-1-billion.html",
    "date": "2023-10-23",
    "keywords": [
        "roche",
        "drug",
        "disease",
        "bowel",
        "antibody",
        "roivant",
        "pfizer",
        "schinecker",
        "development",
        "deal",
        "phase",
        "burger",
        "john",
        "revill",
        "rvt3101",
        "contingent",
        "colitis",
        "antitl1a",
        "inflammatory",
        "group",
        "worldwide",
        "remission",
        "statement",
        "monday",
        "vehicle",
        "manufacture",
        "executive",
        "thomas",
        "record",
        "latestage",
        "trial",
        "cancer",
        "immunotherapy",
        "year",
        "gmt",
        "confirmation",
        "acquisition",
        "charge",
        "march",
        "sense",
        "meanwhile",
        "contender",
        "vivek",
        "ramaswamy",
        "addition",
        "amount",
        "predecessor",
        "severin",
        "schwan",
        "chairman",
        "oncology",
        "business",
        "biotech",
        "decline",
        "avastin",
        "kantonalbank",
        "asset",
        "glance",
        "opportunity",
        "molecule",
        "head",
        "division",
        "teresa",
        "graham",
        "crohns",
        "class",
        "activity",
        "month",
        "teva",
        "co",
        "april",
        "developer",
        "prometheus",
        "stake",
        "japan",
        "therapy",
        "tl1a",
        "potential",
        "difference",
        "reporting",
        "zurich",
        "frankfurt",
        "editing",
        "heine",
        "jason",
        "smith"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}